<DOC>
	<DOCNO>NCT02595554</DOCNO>
	<brief_summary>Neoadjuvant chemotherapy ( NACT ) radical surgery ( RS ) may possible good outcome concurrent chemoirradiation ( CCRT ) stage IIB cervical cancer . We try verify hypothesis term survival treatment related morbidity .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Radical Surgery Stage IIB Cervical Cancer</brief_title>
	<detailed_description>Patients International Federation Gynecology Obstetrics ( FIGO ) stage IIB cervical cancer eligible study . They receive cisplatin base neoadjuvant chemotherapy ( NACT ) 3 cycle follow radical surgery ( RS ) ( type III V radical hysterectomy plus systematic pelvic lymphadenectomy ) ( arm A ) external beam radiation ( EBRT ) concurrent weekly platinum 40mg/m2 follow brachyradiotherapy ( arm B ) .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm cervical carcinoma Original clinical stage must IIB （FIGO 2009） Histopathology squamous carcinoma , adenocarcinoma adenosquamous carcinoma Age 1865 Patients must give sign informed consent The presence uncontrolled lifethreatening illness Receiving way anticancer therapy Investigator consider patient ca n't finish whole study With normal liver function test ( ALT、AST &gt; 2.5×ULN ) With normal renal function test ( Creatinine &gt; 1.5×ULN ) WBC &lt; 4,000/mm3 PLT &lt; 100,000/mm3</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cervical cancer , Stage IIB , Neoadjuvant chemotherapy</keyword>
</DOC>